Evotec Announces Change in Management BoardLaetitia Rouxel steps down as Chief Financial Officer effective 28 February 2025
Evotec Receives Grant from Korean Government to Develop Novel Antibody-based Treatments for Lung DiseasesYonsei University, Zymedi and Evotec receive US$ 4.5m grant from the Korea Institute of Advanced Technology under the Korean Ministry for Trade, Industry and Energy
Evotec SE announces first projects for LAB eN(2) drug discovery accelerator with Novo NordiskNovo Nordisk and Evotec select three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center to be developed within LAB eN² focusing on cardiometabolic diseases
Evotec Announces Change in Management BoardDr Craig Johnstone steps down as Chief OperatingOfficer effective 31 December 2024
Comment on Withdrawn Non-Binding OfferHAMBURG, GERMANY / ACCESSWIRE / November 22, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480)(
NASDAQEVO)
Comment on Media ReportHAMBURG, GERMANY / ACCESSWIRE / November 14, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT) (SDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480 (
NASDAQEVO) With respect to a media report, Evotec SE ("Company") declares that it has received, without prior contact, a non-binding expression of interest from the listed US biotechnology company Halozyme Therapeutics Inc. regarding a takeover offer addressed to the shareholders of the Company with an offer price of EUR 11.00 per share. The Company will carefully analyze this expression of interest, decide on next steps, and inform the capital market in accordance with the legal requirements.
Evotec Announces Sale of API Manufacturing Facility to Monacum PartnersEvotec divests chemical API-focused CDMO operation in Halle/Westphalia (Evotec DS) to Monacum Partners
Evotec and Bristol Myers Squibb Expand Proteomics PartnershipKey scientific achievements drive the expansion of the pipeline of molecular glue degraders in fields beyond oncology
Just - Evotec Biologics Opens Cutting-Edge Biologics Facility - J.POD(R) Toulouse, France (EU)J.POD® Toulouse, France (EU) brings disruptive, scalable continuous biologics manufacturing technology to the region
Evotec SE Reports 9M 2024 Results: Strategic Progress and Successful Expansion Amid Challenging Market ConditionsGuidance for 2024 confirmed with full-year 2024 revenue and adjusted EBITDA targets on track, despite challenging market conditions
Evotec SE to Announce Results for the First Nine Months 2024 on 06 November 2024HAMBURG, GERMANY / ACCESSWIRE / October 30, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX, ISIN: DE0005664809)(
NASDAQEVO) will announce its financial results for the first nine months of 2024 on Wednesday, 06 November 2024.
Evotec and Novo Nordisk Enter into Technology Development Partnership to Support Next-Generation Cell TherapiesNovo Nordisk will provide funding for technology development activities at Evotec to support clinical and commercial manufacturing of stem cell-based therapies
Evotec and X-Chem Collaborate to Accelerate Early-Stage Drug Discovery
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and X-Chem, leader in DNA-encoded library (DEL) technology, today announced a collaboration agreement focused on accelerating early-stage drug discovery.
Evotec Announces Change in Management BoardDr Matthias Evers steps down as Chief Business Officer effective 01 October 2024
Evotec Announces Progress in Strategic Neuroscience Partnership with Bristol Myers SquibbKey scientific achievement advances the joint neuroscience pipeline and earns a payment of US$ 25 m to Evotec to progress further research
Evotec SE Provides Guidance UpdateHAMBURG, GERMANY / ACCESSWIRE / August 6, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces that it has refined its guidance for the fiscal year 2024.
Evotec SE Reports H1 2024 Results: Challenging Year; Priority Reset for Sustainable Profitable Growth Gaining Momentum, Building on Core StrengthsSoftness in market for Shared R&D Services, with H1 2024 revenues down 7% year-on-year. Continued growth of sales order book in Discovery - higher share of integrated long-term deals will improve revenue contribution beyond 2024
Evotec SE Reports First Half-year 2024 Results on 14 August 2024HAMBURG, GERMANY / ACCESSWIRE / August 7, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) will announce its financial results for the first half-year of 2024 on Wednesday, 14 August 2024.
Evotec Provides Guidance UpdateNavigating through a challenging H1 2024: Unsatisfying revenue dynamics in Shared R&D; Just - Evotec Biologics with mid double-digit revenue growth versus strong comparable basis
Evotec and Pfizer Collaborate to Advance Drug Discovery in FranceMulti-year collaboration will initially focus on early discovery research for metabolic and infectious diseases
Just - Evotec Biologics Expands Tech Partnership for Biosimilars with SandozJust - Evotec Biologics expands partnership with Sandoz for development and commercial manufacturing of biosimilars
Just - Evotec Biologics selected by U.S. Department of Defense for Manufacturing Optimization ProgramHAMBURGSUND, SWEDEN / ACCESSWIRE / June 25, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced that its Seattle-based subsidiary, Just - Evotec Biologics, Inc., was selected by the U.S. Department of Defense ("DOD") to develop an accelerated monoclonal antibody ("mAb") development and manufacturing solution for the DOD's Manufacturing Optimization Program. The multi-year program award, valued up to $ 39 m, will support the U.S. Government's effort to enhance its rapid response capabilities for biologics medical countermeasures ("MCMs").
Evotec Announces Progress in Neuroscience Collaboration with Bristol Myers SquibbHAMBURG, GERMANY / ACCESSWIRE / June 12, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) announced today that the Company has reached important scientific progress within its neuroscience collaboration with Bristol Myers Squibb (
NYSEBMY) triggering a research payment of US$ 20 m to Evotec. A target-based programme progresses into late pre-clinical development, further contributing to the fast-growing and promising pipeline of discovery to clinical-stage programmes in neurodegeneration that the partnership has generated.
